# US 9,750,245 B2 · Topical use of an antimicrobial formulation

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 9,750,245 B2
- Document ID: US9750245B2
- Status: Granted
- Kind: B2
- Application number: 13/790,911
- Filed: 2013-03-08
- Published: 2014-09-11
- Granted: 2017-09-05
- Earliest claimed: 2013-03-08
- Assignees: Laboratoire M2
- Applicants: Laboratoire M2
- Inventors: Gaetan Lemire; Ulysse Desranleau Dandurand; Sylvain Quessy; Ann Letellier
- Web page: https://patentgrep.com/patent/US9750245B2

## CPC

- A01N 31/08: Oxygen or sulfur directly attached to an aromatic ring system
- A01N 31/16: with two or more oxygen or sulfur atoms directly attached to the same aromatic ring system
- A61K 9/0014: {Skin, i.e. galenical aspects of topical compositions (non-active ingredients are additionally classified in A61K47/00; A61K9/0009, A61K9/0021, A61K9/7015, A61K9/7023 take precedence; cosmetic preparations A61K8/00, A61Q; preparations for wound dressings or bandages A61L26/00)}
- A61K 31/05: Phenols {(cannabinoids A61K31/658)}
- A61K 47/10: Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
- A61K 47/12: Carboxylic acids; Salts or anhydrides thereof
- A61K 47/20: containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
- A61K 47/26: Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
- A61K 47/44: Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin (synthetic glycerides, e.g. medium-chain triglycerides, A61K47/14)
- A61K 47/46: Ingredients of undetermined constitution or reaction products thereof, e.g. skin, bone, milk, cotton fibre, eggshell, oxgall or plant extracts
- A61P 11/02: Nasal agents, e.g. decongestants
- A61P 17/00: Drugs for dermatological disorders
- A61P 17/02: for treating wounds, ulcers, burns, scars, keloids, or the like
- A61P 27/16: Otologicals
- A61P 31/00: Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P 31/02: Local antiseptics
- A61P 31/04: Antibacterial agents
- A61P 31/10: Antimycotics
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- Y02A 50/30: Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
- A01N: PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF (preservation of food or foodstuff A23); BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES (preparations for medical, dental or toiletry purposes which kill or prevent the growth or proliferation of unwanted organisms A61K); PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- Y02A: TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE

## Abstract

The present document describes a method of reducing a microbial presence on at least one part of a subject by topically contacting the subject's part with an antimicrobial formulation comprising: a) at least one antimicrobial isolated or synthetic phenolic compound of natural origin; b) at least one surfactant sufficient to form a solution or dispersion of said phenolic compound in an aqueous carrier; c) a solvent for dissolving said phenolic compound; and d) a sufficient aqueous carrier quantity to make 100% (w/w).

## Claims

### Claim 1

A method of preventing or treating a hoof bacterial infection on at least one hoof of a live hoofed animal having a bacterial presence thereon, the method consisting of topically applying to said hoof an antibacterial formulation for a time sufficient to reduce said bacterial presence, said antibacterial formulation consisting of:
a) one antibacterial isolated or synthetic phenolic compound of natural origin selected from the group consisting of thymol and carvacrol;
b) at least one surfactant sufficient to form a solution or dispersion of said phenolic compound in water;
c) a solvent for dissolving said phenolic compound; and
d) a sufficient water quantity to make 100% (w/w).

### Claim 2 (depends on 1)

The method of claim 1, wherein phenolic compound is from about 0.05% to about 25% (w/w) of said formulation.

### Claim 3 (depends on 1)

The method of claim 1, wherein said surfactant is from about 0.1% to about 15% (w/w) of said formulation.

### Claim 4 (depends on 1)

The method of claim 1, wherein said solvent is from about 0.1% to about 40% (w/w) of said formulation.

### Claim 5 (depends on 1)

The method of claim 1, wherein said phenolic compound is thymol.

### Claim 6 (depends on 1)

The method of a claim 1, wherein said surfactant is selected from the group consisting of sodium lauryl sulfate, sorbitan stearate, sodium laureth sulfate, sarkosyl, cocamidopropyl betaine (CAPB), sodium lauryl ether sulfonate, alkyl benzene sulfonates, nonylphenol ethoxylate, sorbitan esters and ether ethoxylate.

### Claim 7 (depends on 1)

The method of claim 1, wherein said hoof bacterial infection is chosen from a hoof rot, hoof scald, hoof abscesses, and combinations thereof.

### Claim 8 (depends on 1)

The method of claim 1, wherein topically applying is with one of a spray, a bath, a footbath, a direct application, a wipe, a cream, an ointment, or an unguent.

### Claim 9 (depends on 1)

The method of claim 1, wherein said hoof bacterial infection is a lesion.

### Claim 10 (depends on 1)

The method of claim 1, wherein said hoof bacterial infection is one of a salmonella infection, an E. Coli infection, a staphylococcal infection, a spirochete infection, an impetigo, an ecthyma, a carbunculosis, a folliculitis, an erysipelas, an african tick bite fever, an arcanobacterium haemolyticum infection, a botryomycosis, a brucellosis, a canker, a chlamydial infection, a chronic lymphangitis, a chronic recurrent erysipelas, a cutaneous anthrax infection, a cutaneous diphtheria infection, a cutaneous group B streptococcal infection, a cutaneous pasteurella hemolytica infection, a cutaneous streptococcus iniae infection, adermatitis gangrenosa, a desert sore, a digital dermatitis, a ecthyma gangrenosuma erythrasma, a foot abscess, a furunculosis, a gas gangrene, a glanders, a gram-negative folliculitis, a helicobacter cellulitis, an infected oil gland, an interdigital dermatitis, an interdigital phlegmon, an Italian foot rot a leptospirosis, a Listeria monocytogenes infection, a listeriosis, a melioidosis, a necrotizing fasciitis, a pasteurellosis, a pododermatitis, a primary gonococcal dermatitis, a salmonellosis, a super foot rot, or a toxic shock syndrome.

### Claim 11 (depends on 9)

The method of claim 9, wherein said lesion is one of an ulcer, a diabetic ulcer, a furuncle, a carbuncle, a fissure, a crack, or a blister.

### Claim 12 (depends on 1)

The method of claim 1 wherein said live hoofed animal is livestock.

### Claim 13 (depends on 1)

The method of claim 1 wherein said live hoofed animal is cattle.

### Claim 14 (depends on 1)

The method of claim 1 wherein said live hoofed animal is a dairy cow.

### Claim 15

A method of preventing or treating a hoof bacterial infection on at least one hoof of a live hoofed animal having a bacterial presence thereon, the method consisting of topically applying to said hoof an antibacterial formulation for a time sufficient to reduce said bacterial presence, said antibacterial formulation consisting of:
a) one antibacterial isolated or synthetic phenolic compound of natural origin selected from the group consisting of thymol and carvacrol;
b) at least one surfactant sufficient to form a solution or dispersion of said phenolic compound in water;
c) a solvent for dissolving said phenolic compound; and
d) a sufficient water quantity to make 100% (w/w), and
e) a sequestering agent.

### Claim 16 (depends on 15)

The method of claim 15, wherein said sequestering agent is from about 0.01% to about 10% (w/w) of said formulation.

### Claim 17 (depends on 15)

The method of claim 15, wherein said sequestering agent is selected from the group consisting of ethylene diamine tetraacetic acid (EDTA) sodium salt, sodium gluconate, sodium citrate, citric acid, trisodium NTA, trisodium ethylene disuccinate, sodium phosphate and sodium choleate.

### Claim 18 (depends on 15)

The method of claim 15, wherein said phenolic compound is from about 0.05% to about 25% (w/w) of said formulation.

### Claim 19 (depends on 15)

The method of claim 15, wherein said surfactant is from about 0.1% to about 15% (w/w) of said formulation.

### Claim 20 (depends on 15)

The method of claim 15, wherein said solvent is from about 0.1% to about 40% (w/w) of said formulation.

### Claim 21 (depends on 15)

The method of claim 15, wherein said phenolic compound is thymol.

### Claim 22 (depends on 15)

The method of a claim 15, wherein said surfactant is selected from the group consisting of sodium lauryl sulfate, sorbitan stearate, sodium laureth sulfate, sarkosyl, cocamidopropyl betaine (CAPB), sodium lauryl ether sulfonate, alkyl benzene sulfonates, nonylphenol ethoxylate, sorbitan esters and ether ethoxylate.

### Claim 23 (depends on 15)

The method of claim 15, wherein topically applying is with one of a spray, a bath, a footbath, a direct application, a wipe, a cream, an ointment, or an unguent.

### Claim 24 (depends on 15)

The method of claim 15, wherein said hoof bacterial infection is a lesion.

### Claim 25 (depends on 15)

The method of claim 15, wherein said bacterial infection is one of a salmonella infection, an E. Coli infection, a staphylococcal infection, a spirochete infection, an impetigo, an ecthyma, a carbunculosis, a folliculitis, an erysipelas, an african tick bite fever, an arcanobacterium haemolyticum infection, a botryomycosis, a brucellosis, a canker, a chlamydial infection, a chronic lymphangitis, a chronic recurrent erysipelas, a cutaneous anthrax infection, a cutaneous diphtheria infection, a cutaneous group B streptococcal infection, a cutaneous pasteurella hemolytica infection, a cutaneous streptococcus iniae infection, a dermatitis gangrenosa, a desert sore, a digital dermatitis, a ecthyma gangrenosuma erythrasma, a foot abscess, a furunculosis, a gas gangrene, a glanders, a gram-negative folliculitis, a helicobacter cellulitis, an infected oil gland, an interdigital dermatitis, an interdigital phlegmon, an Italian foot rot a leptospirosis, aListeria monocytogenes infection, a listeriosis, a melioidosis, a necrotizing fasciitis, a pasteurellosis, a pododermatitis, a primary gonococcal dermatitis, a salmonellosis, a super foot rot, or a toxic shock syndrome.

### Claim 26 (depends on 15)

The method of claim 15 wherein said live hoofed animal is livestock.

### Claim 27 (depends on 15)

The method of claim 15 wherein said live hoofed animal is cattle.

### Claim 28 (depends on 15)

The method of claim 15 wherein said live hoofed animal is a dairy cow.